Ivabradine Aurobindo

Ivabradine, the active ingredient in Ivabradine Aurobindo, is an If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is used to manage chronic stable angina and heart failure with reduced ejection fraction in adult patients. GNH USA supplies Ivabradine Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine is employed in cardiovascular conditions that involve abnormal heart‑rate regulation.

- Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate without affecting contractility. - Heart failure with reduced ejection fraction: improves symptoms and may lower hospitalization risk by decreasing heart rate. - Patients unable to tolerate beta‑blockers: provides heart‑rate reduction as an alternative therapeutic option.

Ivabradine may cause a range of adverse reactions, most of which are related to its heart‑rate lowering action and visual processing.

Common Side Effects: - Phosphenes (transient visual bright spots) - Bradycardia (heart rate below 50 bpm) - Headache - Dizziness - Fatigue

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention - Atrial fibrillation or other arrhythmias - Severe hypotension - Persistent visual disturbances - Allergic reactions such as rash or angioedema

Before initiating therapy, clinicians should evaluate cardiac status and concomitant medications.

- Cardiac monitoring: obtain baseline heart rate and ECG. - Hepatic impairment: avoid in severe liver disease. - Sick sinus syndrome: contraindicated unless a pacemaker is present. - CYP3A4 inhibitors: do not co‑administer strong inhibitors (e.g., ketoconazole). - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at below 25°C: keep in the original pack, protect from moisture.

Ivabradine interacts with several drug classes that influence heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause excessive bradycardia. - Concomitant bradycardic agents (beta‑blockers, digoxin): risk of severe heart‑rate reduction. - Other If‑channel inhibitors: additive effect on heart‑rate control.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may increase plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - QT‑prolonging drugs (e.g., sotalol, amiodarone): monitor ECG for arrhythmias.